RECOMBINANT HUMAN ACTIVATED PROTEIN C (rhAPC) PRODUCES A TREND TOWARD IMPROVEMENT IN MORBIDITY AND 28 DAY SURVIVAL IN PATIENTS WITH SEVERE SEPSIS